Single visit clinical validation of screenfire, a low-cost HPV test: efficacy and cost effectiveness (scale)

Active Project Grant Awarded Last action

Award ID
R01CA266059
Recipient
Awarding agency
Obligated
$6,272,095

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date 91% complete
Funding
  • $5,693,294.00 Federal
  • $578,801.00 Non-federal
Place of performance
Cleveland, OH 44195, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
In 2018, the world health organization (who) called for action towards achieving the global elimination of cervical cancer. A strategy for achieving this goal was ratified by member states in august 2020. The who plan calls for an aggressive approach of vaccination, screening, and treatment of the human papillomavirus (HPV), the single cause of cervical cancer. In low- and middle-income countries (lmic), which bear 90% of the incidence and mortality of cervical cancer globally, IT is estimated that these goals will not be reached until 2120 - a century from now. One way to markedly shorten this timeline is through HPV self-sampling and immediate treatment for those who screen positive. In order to scale-up HPV there must be a low-cost, effective test that is easy to use in the field. An optimal field test would allow women to collect their own samples without compromising efficacy. The only who prequalified test specifically developed for low resource settings is carehpv, which has relatively good sensitivity when a sample is taken by a clinician, but which performs poorly when self-sampled. There is an urgent need for evaluation of a low-cost self- sampling test that is effective and can be easily implemented in lmic. Ampfire® (atila biosystems, CA), a new low-cost HPV test, has demonstrated high sensitivity in self-collected samples and may perform better than provider-collected carehpv. Furthermore, the current protocol for carehpv requires a 2-day visit because the machines are in a central location and require 3-4 hours for processing. Ampfire® can be run from local locations using a battery-operated PCR machine. Since these tests process in approximately 1 hour, a single- visit approach is feasible, which is more efficient for the health system and more convenient for patients. The purpose of this study is to compare the efficacy of ampfire® versus carehpv for the detection of high grade precancer (cervical intraepithelial neoplasia, grade 2 or higher, or CIN2+) and to compare the efficacy and feasibility of each test through the following aims: aim 1: to compare self-collected ampfire® to standard provider-collected carehpv for the detection of high grade cervical precancer. Aim 2: demonstrate that a single-visit approach using self-collected ampfire® will result in lower loss to follow-up than the current conventional two-visit approach using provider-collected carehpv. Aim 3: perform a cost- effectiveness analysis to compare efficacy, loss to follow-up and generalizability of self-sampled ampfire® HPV versus provider-collected carehpv.

Transactions

Action Federal Non-federal Date
Amendment $539,745 $0
Amendment $53,105 $0
Amendment $53,105 $0
Amendment $477,957 $0
Amendment $477,957 $0
Amendment $503,441 $0
Amendment $503,441 $0
Amendment $180,289 $0
Amendment Development of an HPV stigma assessment scale and a stigma-reducing intervention to improve cervical cancer prevention in EL salvador $180,289 $0
Amendment $522,121 $0
Amendment $522,121 $0
Amendment Development of an HPV stigma assessment scale and a stigma-reducing intervention to improve cervical cancer prevention in EL salvador $522,121 $0
Amendment $578,801 $0
Original award $578,801 $578,801
Show all 14

Subawards

Subrecipient Amount Awarded
President And Fellows Of Harvard College Nicole Campos, Senior Research Scientist at CHDS focuses on evaluating the cost-effectiveness of cervical cancer screening modalities and protocols in low-… $51,022
Basic Health International Inc. Basic Health International (BHI) will serve as the liaison to El Salvador . BHI will hire study personnel to be responsible for submitting the necessary… $1,260,441
Basic Health International Inc. Supplement award: Basic Health International (BHI) will serve as the local coordinating and implementation entity in El Salvador. BHI will be responsible for… $54,787
The Medical College Of Wisconsin, Inc. Juan Felix, DM is Professor of Pathology and Professor of Surgery at the Medical College of Wisconsin. He is also the Chief of Anatomical Pathology and… $32,046
The Medical College Of Wisconsin, Inc. $4,499
University Of North Carolina At Chapel Hill Jennifer Smith, PhD, MPH is a Professor of Epidemiology at the UNC School of Public Health with extensive experience in global HPV and cervical cancer research.… $42,560

Quick answers

Who received award R01CA266059?

R01CA266059 was awarded to Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University by National Cancer Institute (National Institutes of Health) on April 1, 2022.

How much is award R01CA266059 worth?

$6,272,095 has been obligated on R01CA266059: $5,693,294 in federal funding and $578,801 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login